Biomarker Market 2019 | Development Purpose by Top Players Medtronic plc, BG Medicine, Inc., F. Hoffmann-La Roche Ltd., Seimens Healthnineers, Nexus-DX, Qiagen N.V., and Lifesign LLC

Biomarker tests are conducted for diagnosis and drug discovery & development purpose. It offers quick and accurate results, which has led to high demand for biomarkers. In order to cater to growing demand manufacturers are focusing on research & development for new product launches. For instance, in March 2017, the GeneNEWS Limited launched BreastSentry, a new risk stratification test for breast cancer. The BreastSentry incorporates a blood-based biomarker test to determine a woman’s five year and lifetime risk for developing breast cancer.

Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/1530

Furthermore, in February 2018, Genomic Health, Inc. announced commercial launch of the Oncotype DX AR-V7 Nuclus Detect test in the U.S. The test consists of AR-V7 protein, a prognostic and predictive biomarker, used for detection of tumor cells and to provide precise treatments for cancer.

Millipore Sigma, in May 2017, launched a new single molecule counting platform, SMCxPROTM, during the American Association for Cancer Research Annual Meet. The SMCxPRO platform allows researchers to detect or monitor changes in biomarkers, even at extremely low concentration. Such advancement in the biomarker tests is expected to foster growth of the biomarkers market in the near future.

Furthermore, governments of various countries are focusing on initiatives, in order to develop novel techniques in precision medicines. For instance, the U.S. government launched Precision Medicine Initiative (PMI) in 2015, in order to increase awareness and focus on advancements in precision medicine field, which in turn, favors growth of the biomarkers market.

FDA Biomarker Qualification Program was established in 2009 to support the Center for Drug Evaluation and Research’s (CDER's) work with external stakeholders to develop biomarkers that aid in drug development process. Biomarkers are widely used in drug development to improve the success rate and cost effectiveness.

Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1530

Hence, pharmaceutical companies are increasingly outsourcing complex bio analysis to cut down on costs as well as to benefit from specialized expertise from the outsourced companies. This in turn, is enhancing efficiency of the drug development process. For instance, in March 2018, the SenzaGen entered into a license agreement with Burlesson Research Technologies, Inc., (BRT), a contract research organization in the U.S., specializing in immunotoxicology.

Key players are involved in new product launches to cater to increasing demand for biomarkers. For instance, in 2016 Abbott Laboratories launched Point-of-Care i-STAT Alinity, an innovative, handheld blood testing platform. Some of the other key players in biomarkers market include Medtronic plc, BG Medicine, Inc., F. Hoffmann-La Roche Ltd., Seimens Healthnineers, Nexus-DX, Qiagen N.V., and Lifesign LLC.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.